Final Program

WEDNESDAY • MAY 18 395
2:00 Managing Exacerbations of Obstructive Lung Disease
N.G. Shah, MD, Baltimore, MD
2:30 Management of Severe Hypoxemic Respiratory Failure
A. Rogers, MD, MPH, Palo Alto, CA
3:00 Sedation, Delirium, and Mobilization in the ICU
W.D. Schweickert, MD, Philadelphia, PA
D82
BASIC • CLINICAL • TRANSLATIONAL
CLINICAL TOPICS IN PULMONARY MEDICINE
CME Credits Available: 2.0
THE ROAD TO PRECISION MEDICINE IN IPF:
BIOMARKERS AND CLINICAL PREDICTORS
Assemblies on Clinical Problems; Allergy, Immunology and
Inflammation; Respiratory Cell and Molecular Biology
1:30 p.m. - 3:30 p.m. MOSCONE CENTER
Room 135 (North Building, Lower Level)
Target Audience
Anyone interested in idiopathic pulmonary fibrosis, other iinterstitial lung diseases,
outcome prediction, biomarkers and Precision Medicine. Trainees at all levels will
find the information and style of open discussion uniquely informative as will
clinicians, translational researchers, health care delivery experts, and patient
advocacy group members.
Objectives
At the conclusion of this session, the participant will be able to:
• gain and in depth understanding of the role of molecular markers in
implementation of precision medicine approaches in IPF;
• learn new findings on the potential value of lung and BAL molecular
analyses in guiding diagnosis and management of IPF;
• understand findings on the clinical management of patients with IPF.
Despite significant progress in understanding disease mechanisms, genetics,
and approval of two drugs, IPF remains a significant challenge to practicing
physicians, in part because of its grave prognosis and unpredictable course. In
this interactive session we summarize the huge amount of information collected
on the use of molecular and clinical markers and try to answer the question
whether they can be used in clinical practice. Each talk will include a dynamic
interaction with the audience through social media and other tools and after the
talks, the chairs will provide a brief summary of the talks and open them for
discussion. The session will end with a general discussion followed by a vote by
the audience on the feasibility and potential for clinical application of molecular
markers in IPF.
Chairing: R.P. Marshall, MBBS, MD, PhD, Stevenage, United Kingdom
J. Herazo-Maya, MD, New Haven, CT
J.S. Lee, MD, Aurora, CO
1:30 What Does the Clinician Need from Molecular Markers?
H.R. Collard, MD, San Francisco, CA
1:45 The Road to Precision Medicine in IPF Goes Through the Lung
R.G. Jenkins, MD, PhD, Nottingham, United Kingdom
2:01 No Need for Biopsy: BAL Predicts Outcome, New Mechanisms
in IPF
A. Prasse, MD, Hannover, Germany
2:17 It’s Not Your Cells but Your Bugs: The Microbiome in IPF
T.M. Maher, MD, MSc, PhD, London, United Kingdom
2:33 Genetic Markers Can Lead the Way to Precision Medicine in
IPF
T. Fingerlin, PhD, Denver, CO
2:49 All We Need Is One Drop of Blood: Peripheral Blood Markers
Predict Outcome in IPF
N. Kaminski, MD, New Haven, CT
3:05 Will Precision Medicine Be Applicable to IPF? General
Discussion
R.P. Marshall, MBBS, MD, PhD, Stevenage, United Kingdom
J. Herazo-Maya, MD, New Haven, CT
J.S. Lee, MD, Aurora, CO
This session and the International Conference are supported by an educational grant from
Boehringer Ingelheim Pharmaceuticals, Inc.
All CME sessions have been planned and implemented in accordance with the Essential
Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME)
and are free of the control of commercial interests.
D83
BASIC • BEHAVIORAL
CLINICAL • TRANSLATIONAL
CLINICAL TOPICS IN PULMONARY MEDICINE
CME Credits Available: 2.0
COPD EXACERBATIONS: BIOLOGY AND TARGETS
FOR NOVEL TREATMENTS
Assemblies on Clinical Problems; Allergy, Immunology and
Inflammation; Respiratory Cell and Molecular Biology; Respiratory
Structure and Function
1:30 p.m. - 3:30 p.m. MOSCONE CENTER
Room 134 (North Building, Lower Level)
Target Audience
Clinicians, clinical researchers and trainees who are involved in the research
and care of patients with COPD.
Objectives
At the conclusion of this session, the participant will be able to:
• understand what cells and mechanisms are important during COPD
exacerbation;
• understand the potential role of several novel treatments for COPD;
• understand the inflammation is not the only mechanism for targeted
treatment in COPD exacerbations.
This session will be focused on COPD exacerbations and discussed the biology
and targets for novel treatments in this disease.
Chairing: G.J. Criner, MD, Philadelphia, PA
B.R. Celli, MD, Boston, MA
S.I. Rennard, MD, Melbourn, United Kingdom
ATS 2016 • San Francisco
WEDNESDAY AFTERNOON